Compare Recursion Pharmaceuticals Inc (RXRX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Global X Uranium ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.23 (market cap $2.14B), while Global X Uranium ETF trades at $38.89 (market cap $5.48B). The key difference: Global X Uranium ETF is far larger — about 2.6× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Global X Uranium ETF for 62 Days on average.
| RXRX | URA | |
|---|---|---|
Market Cap | $2.14B | $5.48B |
Volume | 30,789,535 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $61.81 |
52-Week Low | $2.84 | $37.52 |
Typical Hold Time | 23 Days | 62 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
URA (Global X Uranium ETF) is trading at $38.96, down 2.43% today amid bearish technical signals. The ETF faces selling pressure with 19 sell signals versus 3 buy signals across technical indicators. Recent news highlights nuclear energy's growth potential from AI power demand and government support, though uranium ETFs have experienced volatility. The fund provides diversified exposure to uranium miners, utilities, and nuclear infrastructure companies.
The nuclear sector shows long-term potential driven by AI energy demands and government investments, but URA faces near-term technical headwinds. Key risks include commodity price volatility and concentrated holdings. Analyst sentiment remains mixed with some seeing value after recent declines while others caution about sector-specific challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
